PRA International
A leading global CRO, PRA is transforming clinical trials through our people, innovation and transparency. We serve clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Havas Life London
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…
Advertising, Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Management consultancies, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Public relations, Regulatory affairs
Sciterion
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…
Streaming Well
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.
Uniphar
Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.
Company Details
Latest Content from PMHub
Did You Hear From Her? If Not Here’s What You Missed in Season 1 of the Award-Winning Season Podcast Series
Press Releases | February 15, 2024 | Medscape Education
What are some of the biggest gaps that women face in healthcare today? “So many I could talk for hours!” said Shikha Jain, MD, FACP, President, CEO, Founder Women in Medicine....
Have you heard from her?
Press Releases | February 15, 2024 | Medscape Education
We’re referring to the renowned women leaders from across the healthcare landscape who were our guests on Season 1 of Medscape Education’s Hear From Her podcast series. The conversations touched...
Clinical trial considerations: Why diversity matters…
White Papers and Resources | February 15, 2024 | Cuttsy + Cuttsy
Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...
Rare Disease Diagnostic Odyssey
Videos and Podcasts | February 14, 2024 | Medscape Education
Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions
Press Releases | February 14, 2024 | Petauri Evidence
Join us live at 1.00pm (GMT)/2.00pm (CET)/8.00am (EST) on Thursday 29th February, to explore rare disease market access challenges and learn more about these high potential markets.
The pitfalls of cutting costs on systematic literature reviews: 11 common issues to avoid
White Papers and Resources | February 14, 2024 | Petauri Evidence
Embarking on a systematic literature review is a critical step in evidence synthesis, providing a foundation for robust decision-making in the healthcare landscape. As with most things, there are ways...
Product launch: What market research when?
White Papers and Resources | February 14, 2024 | Inizio
Get the insights you need, when you need them, for your product launch planning
Clinical trial considerations: Why digital matters…
White Papers and Resources | February 14, 2024 | Cuttsy + Cuttsy
Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.
Top-5 Trends in Virtual KOL Engagement
Press Releases | February 12, 2024 | Impetus Digital
Register now for one of our upcoming webinars (February 26-28)
Therapy Watch launches new tracker covering Alzheimer’s Disease
White Papers and Resources | February 12, 2024 | Inizio
The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.